TNF activation compromise in vivo multilineage reconstituting activity of NOD-SCID repopulating cells
. | Cells . | EE . | Expansion (d) . | Reconstitution . | |||
---|---|---|---|---|---|---|---|
−TNF . | +TNF . | ||||||
Positive mice . | Percent human engraftment . | Positive mice . | Percent human engraftment . | ||||
Exp. 1 | CD34+ | 85 000 | 5-8 | 4/4 | 25 (6-25-34-36) | 0/4 | 0.2 (0-0-0.3-0.5) |
Exp. 2 | CD34+C D38− | 5 000 | 7 | 2/2 | 51 (23-79) | ||
2 700-5 300 | 7 | 1/2 | 0-1.1 | ||||
Exp. 3 | CD34+ | 50 000 | 5 | 3/3 | 8 (0.3-5-18) | 0/3 | 0.3 (0-0-0.9) |
Total | 9/9 | 25 | 1/9 | 0.3 | |||
Exp. 3 | CD34+ | 50 000 | 2 | 3/3 | 2 (0.1-1-5) | 2/3 | 2 (0-2.5-3) |
Exp. 4 | CD34+ | 50 000 | 2 | 3/5 | 5 (0-0.1-0.2-0.3-23) | 3/3 | 8 (0.2-3-21) |
Total | 6/8 | 4 | 5/6 | 5 |
. | Cells . | EE . | Expansion (d) . | Reconstitution . | |||
---|---|---|---|---|---|---|---|
−TNF . | +TNF . | ||||||
Positive mice . | Percent human engraftment . | Positive mice . | Percent human engraftment . | ||||
Exp. 1 | CD34+ | 85 000 | 5-8 | 4/4 | 25 (6-25-34-36) | 0/4 | 0.2 (0-0-0.3-0.5) |
Exp. 2 | CD34+C D38− | 5 000 | 7 | 2/2 | 51 (23-79) | ||
2 700-5 300 | 7 | 1/2 | 0-1.1 | ||||
Exp. 3 | CD34+ | 50 000 | 5 | 3/3 | 8 (0.3-5-18) | 0/3 | 0.3 (0-0-0.9) |
Total | 9/9 | 25 | 1/9 | 0.3 | |||
Exp. 3 | CD34+ | 50 000 | 2 | 3/3 | 2 (0.1-1-5) | 2/3 | 2 (0-2.5-3) |
Exp. 4 | CD34+ | 50 000 | 2 | 3/5 | 5 (0-0.1-0.2-0.3-23) | 3/3 | 8 (0.2-3-21) |
Total | 6/8 | 4 | 5/6 | 5 |
CD34+ or CD34+CD38− CB cells were cultured for 5 to 8 days (experiments 1-3) or 2 days (experiments 3 and 4) in SF medium in KFT3 in the absence or presence of TNF. NOD-SCID mice were transplanted with the EEs of 50 000 to 85 000 CD34+ cells or 2700 to 5300 CD34+CD38− cells as indicated. Data are presented as number of mice positive for human reconstitution with both B and myeloid cells. Also shown is the percentage human engraftment (representing total human reconstitution independent of whether both myeloid and B cells were observed) of individual animals within each group.